These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 33823765)

  • 41. Quercetin as a JAK-STAT inhibitor: a potential role in solid tumors and neurodegenerative diseases.
    Zalpoor H; Nabi-Afjadi M; Forghaniesfidvajani R; Tavakol C; Farahighasreaboonasr F; Pakizeh F; Dana VG; Seif F
    Cell Mol Biol Lett; 2022 Jul; 27(1):60. PubMed ID: 35883021
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature.
    Crowley EL; Fine SC; Katipunan KK; Gooderham MJ
    J Cutan Med Surg; 2019; 23(3):289-297. PubMed ID: 30688081
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream.
    Smith P; Yao W; Shepard S; Covington M; Lee J; Lofland J; Naim A; Sheth T; Parikh B; Yeleswaram S
    Pharmaceutics; 2021 Jul; 13(7):. PubMed ID: 34371735
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Use of Janus Kinase Inhibitors in Vitiligo: A Review of the Literature.
    Relke N; Gooderham M
    J Cutan Med Surg; 2019; 23(3):298-306. PubMed ID: 30902022
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Janus kinase inhibitors in dermatology: A systematic review.
    Shreberk-Hassidim R; Ramot Y; Zlotogorski A
    J Am Acad Dermatol; 2017 Apr; 76(4):745-753.e19. PubMed ID: 28169015
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway.
    Loo WJ; Turchin I; Prajapati VH; Gooderham MJ; Grewal P; Hong CH; Sauder M; Vender RB; Maari C; Papp KA
    J Cutan Med Surg; 2023; 27(1_suppl):3S-24S. PubMed ID: 36519621
    [TBL] [Abstract][Full Text] [Related]  

  • 47. JAK inhibitors for asthma.
    Georas SN; Donohue P; Connolly M; Wechsler ME
    J Allergy Clin Immunol; 2021 Oct; 148(4):953-963. PubMed ID: 34625142
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Concurrent bullous pemphigoid and psoriasis vulgaris successfully treated with Janus kinase inhibitor tofacitinib: A case report and review of the literature.
    Li H; Wang H; Qiao G; Liu Y; Zhang F; Pan F
    Int Immunopharmacol; 2023 Sep; 122():110591. PubMed ID: 37441809
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Application of Baricitinib in Dermatology.
    Zhang J; Qi F; Dong J; Tan Y; Gao L; Liu F
    J Inflamm Res; 2022; 15():1935-1941. PubMed ID: 35330989
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Various Application of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective.
    Sadeghi S; Goodarzi A
    Dermatol Pract Concept; 2022 Nov; 12(4):e2022178. PubMed ID: 36534552
    [TBL] [Abstract][Full Text] [Related]  

  • 51. JAK-STAT inhibitors in Immune mediated diseases: An Overview.
    Shah RJ; Banerjee S; Raychaudhuri S; Raychaudhuri SP
    Indian J Dermatol Venereol Leprol; 2023; 89(5):691-699. PubMed ID: 37609730
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis.
    Roskoski R
    Pharmacol Res; 2023 Mar; 189():106642. PubMed ID: 36754102
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Janus Kinase Inhibitors in Atopic Dermatitis: New Perspectives.
    Munera-Campos M; Carrascosa JM
    Actas Dermosifiliogr; 2023 Sep; 114(8):680-707. PubMed ID: 37105270
    [TBL] [Abstract][Full Text] [Related]  

  • 54. JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyte-endothelial proadhesive interactions.
    Beckman JD; DaSilva A; Aronovich E; Nguyen A; Nguyen J; Hargis G; Reynolds D; Vercellotti GM; Betts B; Wood DK
    J Thromb Haemost; 2023 May; 21(5):1366-1380. PubMed ID: 36738826
    [TBL] [Abstract][Full Text] [Related]  

  • 55. JAK Inhibitors in Cytokine Storm Syndromes.
    Keenan C; Albeituni S; Nichols KE; Hines M
    Adv Exp Med Biol; 2024; 1448():583-600. PubMed ID: 39117841
    [TBL] [Abstract][Full Text] [Related]  

  • 56. JAK inhibitors for the treatment of vitiligo.
    Inoue S; Suzuki T; Sano S; Katayama I
    J Dermatol Sci; 2024 Mar; 113(3):86-92. PubMed ID: 38326166
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tofacitinib in the treatment of refractory eczemas - a case series.
    Duraisamy P; Jagadeesan S; Thomas J
    J Dermatolog Treat; 2022 Sep; 33(6):2873-2875. PubMed ID: 35642323
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of JAK/STAT inhibitors on human monocyte-derived-macrophages stimulated by cigarette smoke extract and lipopolysaccharide.
    Verres Y; da Silva CO; Aljebawi B; Bodin A; Barreto E; Lagente V; Victoni T
    Clin Exp Pharmacol Physiol; 2022 Nov; 49(11):1187-1196. PubMed ID: 35876719
    [TBL] [Abstract][Full Text] [Related]  

  • 59. How suitable are JAK inhibitors in treating the inflammatory component in patients with alopecia areata and vitiligo?
    Moya EC; Bruinsma RL; Kelly KA; Feldman SR
    Expert Rev Clin Immunol; 2022 Mar; 18(3):189-191. PubMed ID: 35107044
    [No Abstract]   [Full Text] [Related]  

  • 60. Emerging trends in clinical research on Janus kinase inhibitors for atopic dermatitis treatment.
    Shih PY; Li CJ; Yong SB
    Int Immunopharmacol; 2023 Nov; 124(Pt B):111029. PubMed ID: 37820425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.